Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
Public ClinicalTrials.gov record NCT00580047. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplant
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is designed to look at the effect of different bone treatment plans on bone loss after kidney or kidney/pancreas transplant.
Study identification
- NCT ID
- NCT00580047
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 59 participants
Conditions and interventions
Conditions
Interventions
- Zoledronic Acid Drug
- Calcium with vitamin D Combination Product
- Alendronate Drug
Drug · Combination Product
Eligibility (public fields only)
- Age range
- 19 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2003
- Primary completion
- Jul 28, 2014
- Completion
- Jul 28, 2014
- Last update posted
- Oct 3, 2023
2003 – 2014
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Renal Insufficiency trials
Other public records listing Renal Insufficiency. Sorted by last update posted; newest first. Not a recommendation.
- NCT07426380: A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function Active, not recruiting
- NCT01524276: Product Surveillance Registry Recruiting
- NCT05592847: A Study of the Effect of a Nurse Navigator Program on High Risk Patients Not yet recruiting
- NCT06001827: SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00580047, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 3, 2023 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00580047 live on ClinicalTrials.gov.